ACP
DRUG

Acuta Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History

Acuta Capital Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.17M Buy
111,996
+27,519
+33% +$2.22M 5.77% 5
2025
Q4 		$6.59M Sell
84,477
-398
-0.5% -$26.6K 4.48% 6
2025
Q3 		$5.15M Buy
84,875
+36,401
+75% +$1.41M 5.32% 6
2025
Q2 		$1.27M Sell
48,474
-11,274
-19% -$338K 1.77% 17
2025
Q1 		$2.16M Sell
59,748
-9,376
-14% -$343K 2.5% 15
2024
Q4 		$2.49M Buy
+69,124
New +$2.43M 2.5% 14

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Acuta Capital Partners's DRUG Position: Q1 2026 in Review

Acuta Capital Partners increased its Bright Minds Biosciences (DRUG) stake by 33% in Q1 2026, buying an estimated $2.22M and bringing the position to 111,996 shares worth $8.17M. The position accounts for 5.77% of the portfolio, ranked #5.

Acuta Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Acuta Capital Partners held 111,996 shares of Bright Minds Biosciences worth $8.17M as of Q1 2026.
  • Acuta Capital Partners bought 27,519 Bright Minds Biosciences shares in Q1 2026, an estimated $2.22M.
  • Bright Minds Biosciences made up 5.77% of Acuta Capital Partners's portfolio in Q1 2026, its #5 holding.
  • Acuta Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.